Myriad and Abbott Enter into Broad Discovery Collaboration
News Apr 12, 2006
The collaboration will leverage proprietary technology from both organizations to identify favorable targets amenable to drug discovery.
Under the five-year research agreement, Myriad will use its genetics, RNA expression profiling, and other discovery technologies, to identify human genes and regulatory networks associated with a variety of diseases.
Myriad will evaluate differences in DNA and the RNA expression between thousands of individuals to identify the genetic basis of disease.
Abbott will advance these genes through its chemical genomics platform to identify targets and leads for drug discovery.
Each company will have exclusive rights to the therapeutic targets and drug lead compounds to expand their therapeutic pipelines.
Myriad will receive approximately 40 percent of the targets with associated lead compounds identified under the collaboration. Abbott will receive approximately 60 percent.
"The combination of technologies achieved through this collaboration will further the drug discovery efforts at both companies and is expected to lead to innovative solutions for a wide range of unmet medical needs," said Dan Norbeck, Ph.D., Vice President, Pharmaceutical Discovery, Abbott.
"We are extremely pleased to be working with Abbott to discover the next generation of lead compounds to treat diseases with major unmet needs," said Peter Meldrum, President and CEO of Myriad Genetics, Inc.
"We will apply our expertise with leading discovery technologies along with Abbott's proprietary chemical genomics platform to produce a set of novel, high-value drug targets and lead compounds."
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018